CAR T remains Madhav Seshadri, MD's top pick for eligible relapsed/refractory DLBCL, though bispecific antibody regimens are viable alternatives.
Madhav Seshadri, MD
Advertisement
Madhav Seshadri, MD, is an assistant professor in the malignant hematology group at UCSF, specializing in lymphoma and chronic lymphocytic leukemia.
Articles by Madhav Seshadri, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Trump Childhood Vaccine Order: What It Means for Parents and Payers
2
CMS Final Rule Ends Federal Medicaid, CHIP Funding for Youth Gender-Affirming Care
3
OCTOPUS Trial Aims to Speed Access to Rare Sarcoma Drugs
4
Payer Barriers and Anatomic Urgency in Vitiligo Treatment
5